| Literature DB >> 28740938 |
Eloá Moreira-Marconi1,2, Danubia C Sá-Caputo1,2, Carla F Dionello2,3, Eliane O Guedes-Aguiar2,4, Cintia R Sousa-Gonçalves2,3, Danielle S Morel2,3, Laisa L Paineiras-Domingos2,3, Patricia L Souza2,3, Cristiane R Kütter2,5, Rebeca G Costa-Cavalcanti2, Glenda Costa2, Patricia C Paiva2,5, Claudia Figueiredo2,5, Samuel Brandão-Sobrinho-Neto2,5, Christina Stark6,7, Marianne Unger8, Mario Bernardo-Filho2.
Abstract
BACKGROUND: Duchenne muscular dystrophy (DMD) is caused by a defective gene located on the X-chromosome, responsible for the production of the dystrophin protein. Complications in the musculoskeletal system have been previously described in DMD patients. Whole body vibration exercise (WBVE) is a treatment that improves musculoskeletal function in movement disorders. The aim of this study was to review the effects of WBVE on functional mobility, bone and muscle in DMD patients.Entities:
Keywords: Duchenne muscular dystrophy; rehabilitation; whole body vibration exercise
Mesh:
Year: 2017 PMID: 28740938 PMCID: PMC5514435 DOI: 10.21010/ajtcam.v14i4S.1
Source DB: PubMed Journal: Afr J Tradit Complement Altern Med ISSN: 2505-0044
Number of publications in the PubMed, Scopus, Science Direct and PEDro databases
| Keywords | PubMed | Scopus | PEDro | Science Direct |
|---|---|---|---|---|
| “Whole Body vibration” and “Duchenne muscular dystrophy” | 3 | 4 | 0 | 119 |
| “Duchenne muscular dystrophy” | 7,881 | 11,825 | 22 | 11,583 |
| “muscular dystrophy” | 20,507 | 460 | 33 | 36,739 |
| Exercise and “Duchenne muscular dystrophy” | 317 | 460 | 5 | 3191 |
| "physical activity” and “Duchenne muscular dystrophy” | 29 | 83 | 0 | 702 |
| “Whole Body vibration” | 1,323 | 2,636 | 184 | 45,902 |
Figure 1Level of Evidence adapted.
Figure 2Flowchart indicating the steps to selected the full papers analysed in this revision.
Data on device of the oscillating/vibratory platform, number of subjects and frequency and amplitude or the peak to peak displacement of the vibration
| Reference | Level of evidence (LE) | PEDro Scale score (quality) | Platform Devices | Number of subjects/sex/age | Frequency(Hz) | Amplitude (mm)/PtPD (mm)(Rauch 2010) |
|---|---|---|---|---|---|---|
| Vry et al, 2014 | IV | 5 (fair) | side-alternating | n=22 (14 children with DMD/boys/mean 8.8 years and 8 children with SMA/5girls, 3boys/mean 9.9 years) | 15-18/ 18-24 | 4 |
| Soperpalm et al, 2013 | IV | 4 (poor) | side-alternating | n=6 (5.7 – 12.5 years, mean age of 6.8 years) | 16-24 | 2/4(PtPD) |
| Myers et al, 2014 | IV | 4 (poor) | side-alternating | n=4 (mean age of 10 years) | 7-20 | Not informed |
DMD – Duchenne muscular dystrophy, SMA – Spinal muscular atrophy, PtPD- peak-to-peak displacement.
Aims, protocol, findings and conclusions identified in the selected papers involving DMD patients and WBV
| Reference | Aim | Protocol | Findings | Conclusion |
|---|---|---|---|---|
| Vry et al, 2014. | To evaluate the safety of WBV training in ambulatory children with DMD and SMA. | Two consecutive days with 2-3 training session per day in hospital. Between each training session, the patient had a break of at least 4 h. One training session consisted of 3 training units, each lasting 3 minutes, with a break of 3 minutes between each unit. After the teaching phase in the hospital, the patients continued with WBV training at home for 8 weeks (4 week with 15-18 Hz and 4 week with 18-20 Hz). They followed by another 4 weeks without training. Primary outcome was safety of the training, assessed clinically and by measuring serum CK levels. Secondary outcome was efficacy as measured by changes in time function test, muscle strength and angular degree of dorsiflexion of the ankles. | In boys with DMD, CK increased by 56% after the first day of training and returned to baseline after 8 weeks of continuous WBV training. No changes in laboratory parameters were observed in children with SMA. Secondary outcomes showed mild, but not significant improvements with the exception of the distance walked in the 6-min walking test in children with SMA, which rose from 371.3 m to 402.8 m (p < 0.01). | WBV training is clinically well tolerated in children with DMD and SMA. The relevance of the temporary increase in CK in DMD during the first days of training is unclear, but it is not related to clinical symptoms or deterioration. |
| Soperpalm et al, 2013. | To study the tolerability of WBV exercise in patients with DMD and its effects on muscle and bone. | WBV was performed two to three times a week for three month. Motor function, muscle strength, bone mass and biomarkers of bone and mineral metabolism were analyzed before and after the WBV period at 0, 3, 6 and 12 months. | No changes in CK activity were found, indicating that the WBV exercise did not further damage the skeletal muscle. No significant changes in bone mass, muscle strength or bone markers were found. There was a non-significant trend for the bone formation marker, bone-specific alkaline phosphate, to increase after three months of WBV. The bone formation marker levels returned to baseline three months after discontinuing WBV. | WBV therapy appears to be safe and well tolerated among ambulatory DMD patients. The potential benefits of WBV on bone and muscle in DMD remain to be elucidated. |
| Myers et al, 2014. | To evaluate the vibration therapy in patients with DMD. | All patients participated in a 4-week training period involving WBV sessions three time per week. Serum CK was measured, and adverse effects reviewed at each session with functional mobility assessed before and after the training period. | No major changes in functional mobility in the DMD patients were found. One patient had a transient increase in CK during the study; but, levels of this enzyme were stable when comparing the pre-training and post training values. Some patients reported subjective improvement during the training period. | Side-alternating vibration therapy is well tolerated in children with DMD and may have potential to improve or maintain functional mobility and strength in these patients. |
WBV - whole body vibration, DMD - Duchenne muscular dystrophy, SMA - spinal muscular atrophy, CK – creatine kinase.